Communiqués BridgeBio Pharma, Inc.

Actions

BBIO

US10806X1028

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
27,05 ^USD	-0,26 %		-3,43 %	-32,99 %

04/06	Mise à jour sectorielle : Les actions du secteur de la santé sont stables avant la cloche mardi	MT
04/06	L'essai de phase 2 de BridgeBio Pharma sur l'infigratinib montre un "profil d'innocuité bien toléré" ; début du recrutement pour l'essai de phase 3	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO	07/06	PR
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference	06/06	GL
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	05/06	BU
BridgeBio Pharma : BBIO – Infigratinib – PROPEL 2 Data Update and ACCEL Program Initiation	04/06	PU
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia	04/06	GL
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024	03/06	GL
BridgeBio Pharma : BBIO – Encaleret for ADH1 – ENDO 2024 Characteristics of Adults with ADH1 enrolled in CLARIFY	03/06	PU
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma's Phase 3 ATTRibute-CM Study	30/05	AQ
BridgeBio Pharma : BBIO Acoramidis (AG10) TTR ISA 2024 Featured research in the ATTR CM landscape	29/05	PU
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	29/05	GL
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis achieves early reduction in cardiovascular death or hospitalization in transthyretin amyloid cardiomyopathy (ATTR-CM)	29/05	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Acoramidis treatment related increase in serum TTR is associated with lower cardiovascular mortality in ATTR CM	29/05	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients	29/05	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Early increase in serum transthyretin level is an independent predictor of improved survival in ATTR cardiomyopathy	29/05	PU
BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Rationale & design of ACT-EARLY	29/05	PU
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting	24/05	GL
BridgeBio Pharma : BBIO BBP 418 – MENA 2024 – Oral Presentation	20/05	PU
BridgeBio Pharma : Bank of America Merrill Lynch Healthcare Conference 2024 Presentation	15/05	PU
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	15/05	GL
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024	14/05	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués BridgeBio Pharma, Inc.

Actions

BBIO

US10806X1028

Communiqués

Filtres